NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, Price Target & More

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported $2.98 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.78 by $0.20. The specialty pharmaceutical company had revenue of $444.61 million for the quarter, compared to analysts' expectations of $435.69 million. Jazz Pharmaceuticals had a return on equity of 23.78% and a net margin of 26.51%. The company's quarterly revenue was up 18.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.31 EPS. View Jazz Pharmaceuticals' Earnings History.

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for Jazz Pharmaceuticals.

Jazz Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $12.75-13.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.00. The company issued revenue guidance of $1.88-1.93 billion, compared to the consensus revenue estimate of $1.89 billion.

20 brokerages have issued 1 year price targets for Jazz Pharmaceuticals' stock. Their predictions range from $150.00 to $211.00. On average, they expect Jazz Pharmaceuticals' share price to reach $183.0375 in the next year. View Analyst Ratings for Jazz Pharmaceuticals.

Some companies that are related to Jazz Pharmaceuticals include Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF) and Perrigo (PRGO).

Media coverage about JAZZ stock has trended somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a media sentiment score of 0.20 on Accern's scale. They also gave news coverage about the specialty pharmaceutical company an impact score of 47.21 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Jazz Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.44%), Westfield Capital Management Co. LP (2.01%), Boston Partners (1.78%), FIL Ltd (1.51%), Wells Fargo & Company MN (0.77%) and Amundi Pioneer Asset Management Inc. (0.72%). Company insiders that own Jazz Pharmaceuticals stock include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals.

JAZZ stock was sold by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., American Century Companies Inc., BlackRock Inc., Boston Partners, KBC Group NV, Royal Bank of Canada, Schroder Investment Management Group and Franklin Resources Inc.. Company insiders that have sold Jazz Pharmaceuticals company stock in the last year include Bruce C Cozadd, Iain Mcgill, Karen J Wilson, Matthew P Young, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals.

JAZZ stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Systematic Financial Management LP, Summit Trail Advisors LLC, LSV Asset Management, Baird Financial Group Inc., Point72 Asset Management L.P., Dimensional Fund Advisors LP and Atlantic Trust Group LLC. Company insiders that have bought Jazz Pharmaceuticals stock in the last two years include Karen L Smith and Kenneth W O'keefe. View Insider Buying and Selling for Jazz Pharmaceuticals.

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JAZZ stock can currently be purchased for approximately $178.50.

Jazz Pharmaceuticals has a market capitalization of $10.86 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]